Navigation Links
AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy
Date:9/24/2010

Drug Administration (FDA) has designated AMT-080, a gene therapy for Duchenne muscular dystrophy (DMD) as an orphan drug. In October 2009, the Committee for Orphan Medical Products of the European Medicines Agency granted AMT-080 orphan designation for the same indication in the European Union.

AMT has shown efficacy in studies of a preclinical model of DMD. These proof of concept studies demonstrated that AMT's technology resulted in functional dystrophin synthesis in both the heart and skeletal muscles, leading to the prevention of muscular dystrophy. These data are strengthened by a study in which this gene therapy approach was shown to successfully restore dystrophin activity in diseased human muscle cells obtained from biopsies of DMD patients. A Phase I/II clinical trial is scheduled to start by the end of 2012.

AMT has received an Innovation Credit of up to EUR 4 million from the Dutch government to support the development of AMT's gene therapy treatment for Duchenne Muscular Dystrophy (DMD). The credit is granted by SenterNovem, an agency of the Dutch Ministry of Economic affairs.

"It is exceptional that we have been able to reveal the promise of this therapy to the FDA in this early stage of the development. We believe our proven adenoassociated viral vector technology used in all our gene therapy products provides a distinct advantage. AMT has successfully conducted three clinical trials with its lead product Glybera that employs this technology, confirming that AAV-based delivery technology is safe and efficacious," noted Jörn Aldag, CEO of Amsterdam Molecular Therapeutics.

The FDA's orphan drug designation is intended to encourage research and development of new therapies for diseases that affect fewer than 200,000 U.S. residents. As a designated orphan drug, AMT-080 is eligible for tax credits based on its clinical development costs, as well as assistance from the FDA in guiding the drug through the regulatory
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
2. NephRx Corp. Receives Orphan Drug Designation for NX001 for Prevention of Delayed Kidney Graft Function
3. MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
4. NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
5. Renhuang Receives AAA(1) Rating from Chinese Academy of International Trade & Economic Cooperation of Ministry of Commerce
6. Keck Graduate Institute Receives $3.6 Million NIH Grant
7. MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
8. IIVS Receives First Mark Twain Ethical Science Award for Successes In Replacing Animals for Chemical and Product Safety Testing
9. Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection
10. China Agritech, Inc. Receives $10 Million From Warrant Exercise by The Carlyle Group
11. Chiasma Receives Orphan Drug Designation From the FDA for Octreolin™ for the Oral Treatment of Acromegaly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 This report is a ... industry. For an overview analysis, the report introduces ... chain structure, industry overview, policy analysis, and news ... has witnessed rapid development with key manufacturers ... This report mentions quartz tubing upstream raw materials ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that ... with PVM technology , is now available. The ... tool continuously captures high-resolution images under a wide ... prepares a report pairing the most relevant images ... This compelling blend of high resolution images and ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... and AMSTERDAM, The Netherlands, March 24, Agendia, a ... the Company is scheduled to present at the ... on Thursday,April 2, 2009. Presented by BioCentury and ... reputation as a major biotech investment,event, matching strong ...
... GeneGo, Inc., the leading systems biology tools company, announced ... Health at the South London and Maudsley NHS Foundation ... MetaMiner CNS Partnership Program. Professor Simon Lovestone, Centre Director, ... for this project. The goal of the program ...
... proprietary adipocyte differentiation kits -SAN DIEGO and NEW ... a co-exclusive license to market CellDesign,s AdipoDesign Starter ... grow and study adipocytes from adipogenic progenitor cells. ... provider of leading stem cell research technologies and ...
Cached Biology Technology:The NIHR Biomedical Research Centre for Mental Health London has Joined the MetaMiner CNS Partnership Program 2The NIHR Biomedical Research Centre for Mental Health London has Joined the MetaMiner CNS Partnership Program 3The NIHR Biomedical Research Centre for Mental Health London has Joined the MetaMiner CNS Partnership Program 4Stemgent, CellDesign Sign Co-Exclusive Marketing Agreement on Stem Cell-Based Adipocyte Research Products 2
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:11/21/2014)...  Earlier this year Donald Spector , Chairman ... of the most prolific inventors in the world, got ... Smartphones to third party agencies. Spector envisioned this technology ... the earliest known patents in this area. Now major ... child care, elder care and hospital applications. This technology ...
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... running motions and whether the hips, knees or ankles are ... North Carolina State University show that the hips generate more of ... the power when humans run. Knees provide approximately one-fifth or less ... The research could help inform the best ways of building ...
... by motor control and psychology researchers at Indiana University ... feature of bipolar disorder, not just a random symptom, ... brain affected by the psychiatric disorder and new potential ... control and other motor control issues are frequently experienced ...
... wealth of health information hiding in the human immune ... the many and complex roles that the immune system ... to addressing specific health issues. Now, research led by ... shown that a new generation of microchips developed by ...
Cached Biology News:Hips take walking in stride; ankles put best foot forward in run 2Bipolar disorder: Mind-body connection suggests new directions for treatment, research 2Bipolar disorder: Mind-body connection suggests new directions for treatment, research 3Bipolar disorder: Mind-body connection suggests new directions for treatment, research 4Improving health assessments with a single cell 2Improving health assessments with a single cell 3
... targets including proteins and to their modification ... antigens. A&Gs service is divided into ... 40 days (duration may vary slightly dependent ... I: Immunization, test bleed and fusion; $2,500 ...
... Synthetic peptide derived from the N-terminal ... 17 open reading frame 37 (C17orf37 protein) ... C35 protein. On Western blots it identifies ... Reactivity: Human (positive control: full-length human ...
... Two separate vials containing 200 ... same sequence used as antigens for ... 160890) To be ... cyclase polyclonal antiserum (Catalog No. 160890) ...
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
Biology Products: